Your search for non small cell lung cancer returned 14 results

Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.

Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy, a study suggests.

The approval was based on data from the KEYNOTE-091 trial.

Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer.

Krazati is a highly selective and potent oral small molecule inhibitor of KRASG12C.

Eight of nine patients with major pathological response (MPR) were alive and disease-free at five years, while six of 11 without MPR experienced relapse

The ready-to-dilute formulation was developed to eliminate the reconstitution step with Alimta.

Despite NCCN guidelines recommending FDG PET/CT, 43.6 percent of patients were imaged with CT alone before subsequent radiation therapy

Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.

A regulatory decision is expected on November 27, 2023.